Dianthus Therapeutics, Inc. filed its quarterly report on Form 10-Q with the SEC on November 4, 2026, covering the fiscal quarter ended September 30, 2026, disclosing a share count of 56,312,712 common shares outstanding as of November 2, 2026.
Key Highlights
- Share count: As of November 2, 2026, Dianthus Therapeutics reported 56,312,712 shares of common stock, $0.001 par value per share, outstanding.
- Exchange listing: The company's common stock trades on the Nasdaq Capital Market under the symbol DNTH (NASDAQ:DNTH).
- Filer classification: The company is classified as a non-accelerated filer and a smaller reporting company, and is not an emerging growth company.
- Product pipeline disclosed: The filing identifies claseprubart, DNTH212, and DNTH312 as the company's current product candidates under clinical and preclinical development.
- Shell company status: The registrant indicated it is not a shell company, as defined in Rule 12b-2 of the Exchange Act.
- Commission File Number: The filing carries Commission File Number 001-38541, with the company incorporated in Delaware (EIN: 81-0724163).
Dianthus Therapeutics Reports Q3 2026 Filing Position and Pipeline Candidates
Dianthus Therapeutics, Inc., headquartered at 7 Times Square, 43rd Floor, New York, New York 10036, filed its Form 10-Q for the quarterly period ended September 30, 2026, with the U.S. Securities and Exchange Commission. According to the filing, the company had 56,312,712 shares of common stock outstanding as of November 2, 2026. The common stock, which carries a $0.001 par value, is listed on the Nasdaq Capital Market under the trading symbol DNTH.
The filing identifies three product candidates central to the company's clinical and preclinical development activities: claseprubart, DNTH212, and DNTH312. According to the filing, forward-looking statements in the quarterly report address, among other things, "the development or commercial potential of claseprubart, DNTH212, DNTH312 or any other product candidate," as well as anticipated timelines, efficacy, safety profiles, dosing, and regulatory developments. The company cautions that these statements are "subject to substantial risks and uncertainties and are based on estimates and assumptions."
Dianthus Therapeutics is classified in this filing as a non-accelerated filer and a smaller reporting company. It is not classified as a large accelerated filer, an accelerated filer, or an emerging growth company. The filing confirms the company has met its Exchange Act reporting obligations during the preceding 12 months and has submitted all required Interactive Data Files electronically. The company is incorporated in Delaware and carries Internal Revenue Service Employer Identification Number 81-0724163.
What Was Disclosed
Dianthus Therapeutics filed its September 30, 2026 quarterly report disclosing 56,312,712 common shares outstanding, its three named product candidates, its filer classifications, and its continued listing on NASDAQ:DNTH. The report includes condensed consolidated financial statements, management's discussion and analysis, and risk factor disclosures.




Please wait processing your request...